Literature DB >> 26661396

Mortality due to blaKPC Klebsiella pneumoniae bacteraemia.

Yedidah Fraenkel-Wandel1, David Raveh-Brawer2, Yonit Wiener-Well2, Amos M Yinnon3, Marc V Assous4.   

Abstract

OBJECTIVES: To determine the mortality rate secondary to blaKPC Klebsiella pneumoniae (KPC/Kp) bacteraemia, compared with that from ESBL-producing K. pneumoniae (ESBL/Kp) bacteraemia, and to determine associated risk factors.
METHODS: This was a retrospective case-control study of all 68 KPC/Kp bacteraemia patients diagnosed since 2006, matched by year of isolation, gender and age, at a ratio of 1:2, to 136 ESBL/Kp bacteraemia patients.
RESULTS: There were no demographic differences between the two groups, but there were minor clinical differences. Fewer KPC/Kp study patients than ESBL/Kp control patients had a systolic blood pressure <90 mmHg (32/68, 47% versus 86/136, 63%, respectively, P = 0.02) or urinary catheterization (32/68, 47% versus 90/136, 66%, respectively, P = 0.005), while the KPC/Kp bacteraemia group had a greater incidence of acute renal failure (45/68, 66% versus 67/136, 49%, respectively, P = 0.02). There was no difference between the two groups in duration of hospitalization. The mortality rate of the KPC/Kp bacteraemia group was 44/68 (65%) compared with 54/136 (40%) in the ESBL/Kp bacteraemia control group (P = 0.008), which in the multivariate analysis remained highly significant (P < 0.001). Only 11/68 (16%) of KPC/Kp patients were functionally independent at discharge compared with 43/136 (32%) ESBL/Kp patients (P = 0.012).
CONCLUSIONS: The selection of an ESBL/Kp control cohort with a ratio of 1:2 (study versus control group) helped resolve an as yet insufficiently settled question: bacteraemia with KPC/Kp is an independent risk factor for death, justifying the strict adherence to cohorting and isolation procedures.
© The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26661396     DOI: 10.1093/jac/dkv414

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  26 in total

1.  Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.

Authors:  Yawei Zhang; Qi Wang; Yuyao Yin; Hongbin Chen; Longyang Jin; Bing Gu; Liangyi Xie; Chunxia Yang; Xiaobo Ma; Huayin Li; Wei Li; Xiaoqian Zhang; Kang Liao; Sijin Man; Shifu Wang; Hainan Wen; Binbin Li; Zhusheng Guo; Jinjing Tian; Fengyan Pei; Li Liu; Lijun Zhang; Cuimei Zou; Tongping Hu; Jun Cai; Hong Yang; Jiaming Huang; Xianghong Jia; Wenhui Huang; Bin Cao; Hui Wang
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

Review 2.  Metallo-β-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline.

Authors:  Sara E Boyd; David M Livermore; David C Hooper; William W Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 3.  Were all carbapenemases created equal? Treatment of NDM-producing extensively drug-resistant Enterobacteriaceae: a case report and literature review.

Authors:  Vindana Chibabhai; Trusha Nana; Norma Bosman; Teena Thomas; Warren Lowman
Journal:  Infection       Date:  2017-09-15       Impact factor: 3.553

4.  Reducing dissemination of carbapenem-resistant Klebsiella pneumoniae.

Authors:  Matteo Bassetti; Daniele Roberto Giacobbe
Journal:  Ann Transl Med       Date:  2019-12

5.  Risk factors and clinical outcomes of hypervirulent Klebsiella pneumoniae induced bloodstream infections.

Authors:  Jiayang Li; Jianan Ren; Weiping Wang; Gefei Wang; Guosheng Gu; Xiuwen Wu; Ying Wang; Mei Huang; Jieshou Li
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-12-14       Impact factor: 3.267

6.  Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.

Authors:  Pranita D Tamma; Katherine E Goodman; Anthony D Harris; Tsigereda Tekle; Ava Roberts; Abimbola Taiwo; Patricia J Simner
Journal:  Clin Infect Dis       Date:  2016-11-09       Impact factor: 9.079

7.  A model for predicting nosocomial carbapenem-resistant Klebsiella pneumoniae infection.

Authors:  Duo Yang; Zeqiang Xie; Xuli Xin; Wenying Xue; Man Zhang
Journal:  Biomed Rep       Date:  2016-09-07

8.  MgrB-Dependent Colistin Resistance in Klebsiella pneumoniae Is Associated with an Increase in Host-to-Host Transmission.

Authors:  Andrew S Bray; Richard D Smith; Andrew W Hudson; Giovanna E Hernandez; Taylor M Young; Hannah E George; Robert K Ernst; M Ammar Zafar
Journal:  mBio       Date:  2022-03-21       Impact factor: 7.786

9.  Immune stealth-driven O2 serotype prevalence and potential for therapeutic antibodies against multidrug resistant Klebsiella pneumoniae.

Authors:  Meghan E Pennini; Anna De Marco; Mark Pelletier; Jessica Bonnell; Romana Cvitkovic; Martina Beltramello; Elisabetta Cameroni; Siro Bianchi; Fabrizia Zatta; Wei Zhao; Xiaodong Xiao; Maria M Camara; Antonio DiGiandomenico; Elena Semenova; Antonio Lanzavecchia; Paul Warrener; JoAnn Suzich; Qun Wang; Davide Corti; C Kendall Stover
Journal:  Nat Commun       Date:  2017-12-08       Impact factor: 14.919

10.  Preserving Vascular Integrity Protects Mice against Multidrug-Resistant Gram-Negative Bacterial Infection.

Authors:  Teclegiorgis Gebremariam; Lina Zhang; Sondus Alkhazraji; Yiyou Gu; Eman G Youssef; Zongzhong Tong; Erik Kish-Trier; Ashok Bajji; Claudia V de Araujo; Bianca Rich; Samuel W French; Dean Y Li; Alan L Mueller; Shannon J Odelberg; Weiquan Zhu; Ashraf S Ibrahim
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.938

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.